跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07674147
NCT07674147尚未招募1 期

A Clinical Study of the Safety, Efficacy, and Pharmacokinetics of Universal CD19/BCMA-Targeted CAR-T Cell Injection for the Treatment of Autoimmune Diseases in Children and Adolescents

The Children's Hospital of Zhejiang University School of Medicine2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年7月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
30
试验地点
2
主要终点
Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell (CAR-T), in pediatric and adolescent patients with refractory autoimmune diseases, including systemic lupus erythematosus/lupus nephritis (SLE/LN), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), multidrug-resistant nephrotic syndrome (MDR-NS), and refractory IgA nephropathy (IgAN).

Approximately 30 eligible patients will be enrolled and receive a single intravenous infusion of RD06-05 at an initial dose of 6×10⁶ CAR+ T cells/kg, with a potential dose escalation to 10×10⁶ CAR+ T cells/kg following review by a Safety Review Committee (SRC).

详细描述

Study Duration:

Approximately 4 years (2026-2030), with individual participant participation lasting up to 24 months post-infusion.

Follow-up:

Patients are followed for safety, efficacy, PK/PD, and quality of life assessments at predefined time points through 24 months post-infusion.

Key Endpoints:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
5 Years 至 20 Years（Child, Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Voluntary participation with signed informed consent from patient or legal guardian.
  • •Age >=5 to <20 years, male or female.
  • •Important organ function meeting the following requirements (excluding abnormalities related to autoimmune disease activity): a) Bone marrow: ANC >=1.0x10^9/L, hemoglobin >=60 g/L, platelets >=30x10^9/L; b) Liver: ALT <=3xULN (except IIM-related elevation), AST <=3xULN, total bilirubin <=2xULN (<=3xULN for Gilbert syndrome); c) Kidney: eGFR >=30 mL/min/1.73m^2 (lower eGFR or on renal replacement may be allowed if benefit > risk by investigator judgment); d) Cardiac: LVEF >=55% by echocardiogram; e) Pulmonary: No severe lung disease, SpO2 >=92%.
  • •Negative serum or urine pregnancy test for females of childbearing potential at screening.
  • •Females of childbearing potential must use highly effective contraception from at least 28 days before lymphodepletion through 12 months post-infusion. Males must use effective barrier contraception and not donate sperm from start of lymphodepletion through 12 months post-infusion.
  • •Disease-Specific Inclusion Criteria for SLE/LN:
  • •Diagnosis of SLE by 2019 EULAR/ACR or 2012 SLICC criteria.
  • •If renal involvement: kidney biopsy within 2 years showing active nephritis (class III, IV, V, or combination). Renal involvement defined as proteinuria >0.15g/24h, or hematuria, or eGFR <90.Inadequate response to standard therapy: high-dose glucocorticoid (>=1 mg/kg/d prednisone equivalent) + hydroxychloroquine + at least 2 DMARDs for 3 months, or intolerance, or unable to taper steroid to <=5 mg/day at 6 months.
  • •Positive ANA, anti-dsDNA, or anti-Smith antibody.
  • •SLEDAI-2K >=8 and clinical SLEDAI-2K >=4 (renal proteinuria >0.5g/24h or UPCR >500 mg/g or active urinary sediment may waive the clinical SLEDAI-2K requirement).
  • •Physician Global Assessment (PGA) >=1.0 (0-3 VAS).
  • •Disease-Specific Inclusion Criteria for SSc:
  • •Diagnosis of SSc by 2013 ACR/EULAR criteria.
  • •Diffuse cutaneous SSc.
  • •Evidence of active disease (e.g., new SSc within 2 years, new skin involvement or worsening mRSS within 6 months, tendon friction rubs, lung function decline, ILD progression).
  • •FVC >=50% and DLCO >=45% predicted.
  • •Failed or relapsed on conventional therapy (glucocorticoid >0.5 mg/kg/d prednisone equivalent + at least two immunomodulators for >6 months).
  • •Disease-Specific Inclusion Criteria for IIM:
  • •Diagnosis of IIM (dermatomyositis, antisynthetase syndrome, IMNM) by 2017 ACR/EULAR criteria (probability >=55%).
  • •Active disease: at least 2 of 6 core set abnormalities (MMT-8<142, PhGA >=2 cm, PtGA >=2 cm, extra-muscular MDAAT >=2 cm, PedsQL >=60, CK >=1.5xULN).
  • •Positive myositis-specific autoantibody.
  • •Failed or relapsed on conventional therapy (glucocorticoid >1 mg/kg/d prednisone equivalent + at least 2 immunomodulators for >=6 months).
  • •Disease-Specific Inclusion Criteria for IgAN:
  • •Biopsy-confirmed IgA nephropathy.
  • •On ACEi/ARB for >=3 months, and at least one of: a) proteinuria >=500 mg/24h or UPCR >=0.5 mg/mg after >=3 months of steroid + at least one immunosuppressant/biologic; b) eGFR decline >50% within 3 months; c) 22.intolerance to conventional therapy with benefit > risk.
  • •Disease-Specific Inclusion Criteria for MDR-NS:
  • •23.Meets 2025 KDIGO definition of steroid-resistant nephrotic syndrome. 24.At least one of: a) failed to achieve remission after 12 months of two different mechanism steroid-sparing agents (at least one calcineurin inhibitor); b) no remission after 3-6 months of one CNI with benefit > risk; c) intolerance to conventional therapy; d) coexisting systemic disease requiring long-term immunosuppression.
  • •25.Prior kidney biopsy showing minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS).

排除标准

  • •Co-existing autoimmune disease that may interfere with disease activity attribution or add safety risk (unless stable >=3 months and approved).
  • •Prior B-cell/ASC depletion therapy: a) Anti-CD20 or T-cell engager within 3 months (allowed if >3-6 months and CD19+ B-cells > LLN); b) Prior CD19 and BCMA dual-targeted therapy, or CD19 or BCMA targeted therapy within 6 months (allowed if >6 months and B-cells > LLN); c) Other B-cell/ASC targeted therapies require approval.
  • •Rapidly progressive glomerulonephritis (RPGN): >=50% crescents on biopsy, or doubling of serum creatinine within 2 months, or investigator judgment.
  • •Cardiac disease: NYHA class III/IV heart failure, MI, angioplasty/stent, unstable angina, or other severe cardiac disease within 12 months.
  • •Severe CNS disease (traumatic brain injury, impaired consciousness, epilepsy, cerebrovascular ischemia/hemorrhage) that may affect compliance or assessment.
  • •Malignancy history except cured non-melanoma skin cancer or carcinoma in situ, unless disease-free for >=3 years.
  • •Primary immunodeficiency.
  • •Uncontrolled infection (simple UTI or upper respiratory infection allowed).
  • •Known history of HIV, hepatitis C, or syphilis infection.
  • •Active or latent hepatitis B infection.
  • •Positive EBV or CMV DNA or IgM at screening.
  • •History of recurrent tuberculosis.
  • •Prior CAR-T or other transgenic immune cell therapy.
  • •Live attenuated vaccine within 4 weeks before enrollment.
  • •Allergy to any component of the cell therapy product.
  • •Hypersensitivity to tacrolimus or prior grade >=3 tacrolimus-related toxicity requiring hospitalization (exceptions may be approved).
  • •Participation in another clinical trial within 30 days before screening.
  • •Pregnancy, breastfeeding, or unwillingness to use effective contraception.
  • •Any other condition judged by investigator as unsuitable for study.
  • •Disease-Specific Exclusion Criteria for SLE:
  • •Active/unstable neuropsychiatric lupus (seizures, psychosis, organic brain syndrome, CVA, encephalitis, CNS vasculitis) within 90 days requiring intervention.
  • •Prior treatments: belimumab/telitacicept within 4 weeks; ianalumab within 8 weeks unless B-cells > LLN; >1 systemic NSAID within 14 days; inability to wash out NSAID before disease activity assessment; intra-articular/IM glucocorticoid within 6 weeks; immunosuppressant doses above specified limits; initiation or dose change of hydroxychloroquine within 8 weeks; ACEi/ARB/SGLT2 inhibitor dose change within 4 weeks.
  • •Disease flare requiring increased corticosteroids (>20 mg/day prednisone equivalent) or new immunosuppression during screening.
  • •Disease-Specific Exclusion Criteria for IIM:
  • •Severe rhabdomyolysis or CK >=20xULN.
  • •FVC <=60% predicted, or DLCO <=70% predicted, or worsening lung function compared to prior 3-12 months.
  • •Disease-Specific Exclusion Criteria for SSc:
  • •Anti-centromere antibody positive without ATA or anti-RNAP
  • •Clinically significant respiratory disease other than ILD (severe COPD, severe asthma, recent severe respiratory infection, smoking).
  • •FVC <50% or DLCO <40% predicted.
  • •On lung transplant list or expected within 12 months.
  • •History of scleroderma renal crisis within 6 months.
  • •SSc-like disorders (morphea, eosinophilic fasciitis, etc.).
  • •Antifibrotic drugs within 4 weeks (colchicine, D-penicillamine, pirfenidone, tyrosine kinase inhibitors).
  • •Prior chlorambucil, bone marrow transplant, or total lymphoid irradiation.
  • •Disease-Specific Exclusion Criteria for IgAN:
  • •Secondary IgAN (cirrhosis, celiac disease, HIV, malignancy).
  • •Other cause of chronic kidney disease (diabetic nephropathy, other primary glomerulopathy) that may interfere.
  • •Uncontrolled blood pressure.
  • •Prior treatments: hydroxychloroquine dose change within 8 weeks; biologics (infliximab, eculizumab, canakinumab) within 4 weeks; prednisone >30 mg/day or unstable dose; endothelin receptor antagonist within 4 weeks before lymphodepletion.
  • •Disease-Specific Exclusion Criteria for MDR-NS:
  • •Secondary nephrotic syndrome/proteinuria (infection-related, drug-related, systemic disease) that may interfere.
  • •On maintenance dialysis, need for immediate renal replacement, or expected dialysis/transplant within 12 months.
  • •Prior treatments: ACEi/ARB dose change within 4 weeks; glucocorticoid dose adjustment within 2 weeks or need for >10 mg/day prednisone equivalent; 40.disease flare requiring increased steroids (>10 mg/day) or new immunosuppression during screening.

研究组 & 干预措施

RD06-05 Universal CAR-T Therapy

Experimental

Single-arm, open-label: participants receive a single intravenous infusion of RD06-05 (universal CD19/BCMA dual-targeting CAR-T cells) following a lymphodepleting regimen of fludarabine and cyclophosphamide.

干预措施: RD06-05 CART Cell Infusion (Drug)

结局指标

主要结局

Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

时间窗: From signing of informed consent through 90 days post-infusion (for related AEs, up to 24 months post-infusion)

Incidence of TEAEs, SAEs, and AESIs following RD06-05 infusion. AESIs include cytokine release syndrome (CRS) of grade ≥3, immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, graft-versus-host disease (GvHD) of any grade, infections of grade ≥3, secondary malignancies of any grade, and cardiac disorders of any grade.

次要结局

  • Proportion of SLE/LN Patients Achieving LLDAS and DORIS Remission(2 years)
  • Renal Response in SLE/LN Patients with Renal Involvement(2 years)
  • Change in SLE Disease Activity Scores(2 years)
  • Change in SLE Disease Activity Scores(2years)
  • Change in Autoantibody Levels in SLE/LN(2 years)
  • Change in Complement Levels in SLE/LN(2 years)
  • Major Clinical Response in IIM Patients(2 years)
  • Change in Skin and Lung Function in SSc Patients(2 years)
  • Remission and Renal Outcomes in MDR-NS Patients(2 years)
  • Change in Quality of Life (PedsQL 4.0)(2 years)
  • Pharmacokinetics - CAR-T Expansion(2 years)
  • Immunogenicity - Anti-Drug Antibodies (ADA)(2 years)
  • Proteinuria in IgAN Patients(2 years)
  • Renal Function in IgAN Patients(2 years.)
  • Renal Function in IgAN Patients(2 years)
  • Duration of peripheral blood B-cell aplasia(2 years)
  • Pharmacokinetics - CAR-T Persistence(2 years)

研究者

发起方
The Children's Hospital of Zhejiang University School of Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mao Jianhua

Professor

The Children's Hospital of Zhejiang University School of Medicine

研究点 (2)

Loading locations...

相似试验

尚未招募
1 期
Study of SNH-118110 in Advanced Solid TumorsSolid Tumors
NCT07649200ScinnoHub Pharmaceutical Co., Ltd.240
尚未招募
1 期
JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFRSolid Cancers
NCT07510841Biotech Pharmaceutical Co., Ltd.228
招募中
1 期
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
NCT07348653Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.116
尚未招募
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese SubjectsDelirium
NCT07422142Kunming Pharmaceuticals, Inc.54
尚未招募
1 期
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
NCT07615413Jiangsu Hansoh Pharmaceutical Co., Ltd.636